IMPERA MEDICINES
Live / Applied — Second extension granted (statement of use) (as of 06 Jan 2026)
What this means for you
Not registered yet, but its 20 Mar 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98459161
- Mark type
- Stylized text
- Filed
- 20 Mar 2024
- Published for opposition
- 03 Dec 2024
- Attorney of record
- Aaron D. Hendelman
Goods and services
- Class 005 — Pharmaceuticals: medicinal preparations for the treatment of infectious diseases and for use in oncology; biological preparations for the treatment of cancer; anti-cancer preparations; medicinal preparations for the treatment of cardiometabolic diseases; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for the treatment of cardiometabolic diseases; pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, cardiometabolic, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders
- Class 035 — Advertising and business services: Business consultancy in the field of biotechnology; professional business consulting for biotechnology companies; business consulting, business management and providing information in the biotechnology business field; business services, namely, assisting the owners of intellectual property and intangible assets in the field of biotechnology in finding investors
- Class 036 — Insurance and financial services: investment consultancy for biotechnology companies; investment management for biotechnology companies; financial services, namely, investment management and advisory services in the field of biotechnology; intellectual property venture fund management services in the field of biotechnology
- Class 042 — Scientific and technological services: research and development services in the fields of immunology and oncology; research and development services in the field of cardiometabolic diseases; medical research in the field of oncology; medical research in the field of immunology; medical research in the field of cardiometabolic diseases; research, development, engineering and testing services in the field of pharmaceuticals for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, cardiometabolic, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders
Owner
- Impera Medicines, LP, San Diego, CA, US
- Impera Medicines, LP, San Diego, CA, US
Prosecution history
- 06 Jan 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 06 Jan 2026 — SOU EXTENSION 2 GRANTED
- 05 Jan 2026 — SOU EXTENSION 2 FILED
- 05 Jan 2026 — SOU TEAS EXTENSION RECEIVED
- 17 Jun 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 16 Jun 2025 — SOU EXTENSION 1 GRANTED
- 16 Jun 2025 — SOU EXTENSION 1 FILED
- 16 Jun 2025 — SOU TEAS EXTENSION RECEIVED
- 14 Jan 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 03 Dec 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 03 Dec 2024 — PUBLISHED FOR OPPOSITION
- 27 Nov 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 11 Nov 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 04 Oct 2024 — EXAMINER'S AMENDMENT ENTERED
- 04 Oct 2024 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED